scout
|Videos|April 15, 2022

Efficacy Data from the VISION Trial of Lu 177 Vipivotide Tetraxetan

Scott Tagawa, MD, MS, FACP, reviews key efficacy data from the VISION trial of Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (CRPC).

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME